# Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

> **NCT03206255** · — · COMPLETED · sponsor: **Jun Zhang** · enrollment: 940 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia
- Cervical Cancer
- Vaginal Intraepithelial Neoplasia
- Vulvar Intraepithelial Neoplasia
- Persistent Infection

## Interventions

- **PROCEDURE:** 3 doses of HPV 16/18 bivalent vaccine
- **PROCEDURE:** 2 doses of HPV 16/18 bivalent vaccine

## Key facts

- **NCT ID:** NCT03206255
- **Lead sponsor:** Jun Zhang
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2018-08-15
- **Final completion:** 2018-08-15
- **Target enrollment:** 940 (ACTUAL)
- **Last updated:** 2019-01-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03206255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03206255, "Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03206255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*